News

Can Moderna Keep the Beat Streak Alive This Earnings Season?
Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...
McKnight's Long-Term Care News1d
RSV vaccine wanes in older adults over three seasons, trial shows
A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...
MyChesCo on MSN3d
Expanded Recommendation for GSK’s AREXVY Vaccine Targets Adults at Higher Risk for Severe RSV
The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...
Managed Healthcare Executive4d
A Win for Adult RSV Vaccination Amid Vaccine Uncertainty, Hesitancy
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Knowridge Science Report5d
Single-dose RSV vaccine protects older adults across three seasons, global study finds
A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...
Medical Dialogues6d
GSK Arexvy recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices
GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of ...